Reduced Incidence of Severe Palmar-Plantar Erythrodysesthesia and Mucositis in a Prospective Multicenter Phase II Trial with Pegylated Liposomal Doxorubicin at 40 mg/m2 Every 4 Weeks in Previously Treated Patients with Metastatic Breast Cancer

Publisher： Karger

E-ISSN： 1423-0232|70|2|141-146

ISSN： 0030-2414

Source： Oncology, Vol.70, Iss.2, 2006-05, pp. : 141-146

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II Trial of Pegylated Liposomal Doxorubicin-Cyclophosphamide Combination as First-Line Chemotherapy in Older Metastatic Breast Cancer Patients

By  

Oncology, Vol. 73, Iss. 3-4, 2008-04 ,pp. : 210-214

Karger

Access to resources Recommend Favorite

Pyridoxine as Prophylactic Therapy for Palmar-Plantar Erythrodysesthesia Associated with Administration of Pegylated Liposomal Doxorubicin (Caelyx): A Single-Center Experience

By  

Oncology, Vol. 73, Iss. 3-4, 2008-04 ,pp. : 277-278

Karger

Access to resources Recommend Favorite

Multicenter Phase II Study of Pegylated Liposomal Doxorubicin in Combination with Vinorelbine as First-Line Treatment in Elderly Patients with Metastatic Breast Cancer

By  

Oncology Research and Treatment, Vol. 32, Iss. 1-2, 2009-01 ,pp. : 18-24

Karger

Access to resources Recommend Favorite

Trastuzumab Combined with Pegylated Liposomal Doxorubicin in Patients with Metastatic Breast Cancer

By  

Oncology, Vol. 76, Iss. 4, 2009-03 ,pp. : 275-285

Karger

Access to resources Recommend Favorite

Front-Line Chemotherapy with Docetaxel and Gemcitabine Administered Every Two Weeks in Patients with Metastatic Breast Cancer: A Multicenter Phase II Study

By  

Oncology, Vol. 67, Iss. 3-4, 2004-11 ,pp. : 250-256

Karger

Access to resources Recommend Favorite